Table 1.
Summary trial and patient characteristics
| Trial level n (%) or median (range) | Patient level* n (%) or mean (range) | |
|---|---|---|
| Trials and prospective series (n) | 38 | 6116 |
| Phase 1 | 1 | 45 |
| Phase 1/2 | 4 | 245 |
| Phase 2 | 15 | 1,536 |
| Phase 3 | 2 | 638 |
| Prospective | 14 | 1,472 |
| Registry | 2 | 2,180 |
| Patients (n) | 6116 | 6116 |
| Fractions | 5 (4-9) | 5 (4-9) |
| Dose per fraction | 7.25 Gy (5-10 Gy) | 7.4 Gy (5-10 Gy) |
| Average follow-up† | 30 mo (12-115 mo) | 39 mo (12-115 mo) |
| Average age‡ | 68 y (63-77 y) | 68 y (63-77 y) |
| Clinical stage, n (%)§ | ||
| T1 | 28 (88) | 67% |
| T2 | 28 (88) | 31% |
| T3 | 6 (19) | 2% |
| T4 | 1 (3) | 0% |
| Pre-SBRT PSA∥ | 6.8 ng/mL (4.7-72 ng/mL) | 7.5 ng/mL (4.7-72 ng/mL) |
| NCCN risk group (V4.2018) | ||
| Low | 34 (92) | 2745 (45) |
| Intermediate | 29 (78) | 2901 (47) |
| High | 15 (38) | 470 (8) |
| ADT receipt with SBRT¶ | 19 trials | 654 (15%) |
| Number reporting bRFS | 33 (87) | 5778 (95) |
| Number reporting acute or late toxicity | 37 (97) | 6044 (99) |
| Number reporting HRQOL | 25 (66) | 3973 (65) |
| Number using EPIC-26 | 16 (42) | 3293 (54) |
| Number reporting AUA IPSS | 13 (34) | 2399 (39) |
Abbreviations: ADT = androgen-deprivation therapy; AUA = American Urological Association; bRFS = biochemical recurrence-free survival; EPIC = expanded prostate cancer index composite; HRQOL = health-related quality of life; IPSS = International Prostate Symptom Score; NCCN = National Comprehensive Cancer Network; PSA = prostate-specific antigen; SBRT = stereotactic body radiation therapy.
*
Mean values weighted by number of patients per trial.
†
Thirty-eight series report average or median follow-up.
‡
Thirty-four series report average age.
§
Thirty-two series report clinical T stage.
∥
Thirty series report PSA.
¶
Thirty-three series report whether or not ADT was used with SBRT.